SALT LAKE CITY--(BUSINESS WIRE)--Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9,359,637 for the company’s AMPED technology. The newly issued patent for systems and methods for signal amplification, U.S. Patent 9,359,637, broadens coverage of the invention—termed AMPED—to now include methods of use of the technology, not just confined to product kits containing the proprietary signal amplifying polymer, for detection of any diagnostic target of interest such as proteins and nucleic acids.
“The AMPED technology is at the core of our uniquely low-cost and powerful system, one that is capable of answering the ‘what is it?’ question with a low-cost, low-plex test, and the ‘what is causing it?’ question, identified by syndromic multiplex panels,” said Robert D. Jenison, chief technology officer, Great Basin Scientific. “We are pleased that the U.S. Patent Office has seen fit to offer us broad protection as we believe the exceptional sensitivity of AMPED can eventually be useful in fields beyond our current product focus of Molecular Diagnostics.”
The AMPED amplification and detection method uses the Company’s proprietary detection chip, which provides a visible result when the target of interest is present. AMPED’s high sensitivity and specificity will enable the direct detection of pathogens present in clinical samples, even when present in small amounts, without requiring polymerase chain reaction-based (PCR) target amplification, and when implemented in future tests will make it possible for Great Basin to provide PCR-like limits of detection at greatly reduced test times for certain targets of interest. This patent further secures the intellectual property behind Great Basin’s advanced molecular diagnostics technology. With this patent grant, Great Basin now has 6 U.S. patents and 13 patents pending.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.
This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to intellectual property protection from granted patents, use of our proprietary technologies and related statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.